- Home
- LPG vs COLL Comparison
LPG vs COLL Comparison
Compare LPG & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPG
- COLL
- Stock Information
- Founded
- LPG 2013
- COLL 2002
- Country
- LPG United States
- COLL United States
- Employees
- LPG N/A
- COLL N/A
- Industry
- LPG Marine Transportation
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- LPG Consumer Discretionary
- COLL Health Care
- Exchange
- LPG Nasdaq
- COLL Nasdaq
- Market Cap
- LPG 1.0B
- COLL 1.1B
- IPO Year
- LPG 2014
- COLL 2015
- Fundamental
- Price
- LPG $23.61
- COLL $30.78
- Analyst Decision
- LPG Buy
- COLL Strong Buy
- Analyst Count
- LPG 2
- COLL 6
- Target Price
- LPG $43.00
- COLL $42.00
- AVG Volume (30 Days)
- LPG 703.6K
- COLL 439.3K
- Earning Date
- LPG 01-30-2025
- COLL 11-07-2024
- Dividend Yield
- LPG 17.33%
- COLL N/A
- EPS Growth
- LPG N/A
- COLL 757.11
- EPS
- LPG 5.82
- COLL 2.16
- Revenue
- LPG $498,825,986.00
- COLL $599,245,000.00
- Revenue This Year
- LPG N/A
- COLL $13.20
- Revenue Next Year
- LPG N/A
- COLL $17.63
- P/E Ratio
- LPG $3.94
- COLL $14.32
- Revenue Growth
- LPG 1.76
- COLL 9.62
- 52 Week Low
- LPG $22.46
- COLL $28.97
- 52 Week High
- LPG $51.66
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- LPG 37.28
- COLL 48.70
- Support Level
- LPG $22.62
- COLL $29.67
- Resistance Level
- LPG $24.75
- COLL $31.10
- Average True Range (ATR)
- LPG 0.80
- COLL 0.98
- MACD
- LPG 0.20
- COLL 0.26
- Stochastic Oscillator
- LPG 48.84
- COLL 69.41
About LPG Dorian LPG Ltd.
Dorian LPG Ltd is an international liquefied petroleum gas shipping company focused on owning and operating gas carriers, or VLGCs. The company currently owns and operates around 22 modern VLGCs, including nineteen new fuel-efficient 84,000 cbm ECO-design VLGCs. Dorian LPG has offices in Connecticut, USA, London, United Kingdom, and Athens, Greece.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.